Skip to content
Back to MLTX

MoonLake Immunotherapeutics

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
27
Purchases
0
Sales
27
Purchase value
$0.00
Sale value
$81.07M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Kristian ReichChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jul 29, 2026Period of report Jul 27, 20260001213900-26-082804
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 27, 2026
Class A ordinary shares, par value $0.0001 per shareF1F21,100$20.00$22.00K2,711,198IndirectSee footnote.
Filing footnotes · 2
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
  2. F2Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
Open on SEC EDGAR
Kristian ReichChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jul 23, 2026Period of report Jul 21, 20260001213900-26-080869
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 22, 2026
Class A ordinary shares, par value $0.0001 per shareF1F32,448$20.00$48.96K2,712,298IndirectSee footnote.
SaleJul 21, 2026
Class A ordinary shares, par value $0.0001 per shareF1F2F350,000$20.02$1.00M2,714,746IndirectSee footnote.
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
Open on SEC EDGAR
Kristian ReichChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jul 21, 2026Period of report Jul 20, 20260001213900-26-080133
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 20, 2026
Class A ordinary shares, par value $0.0001 per shareF1F2F343,700$20.09$877.93K2,764,746IndirectSee footnote.
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.25. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
Open on SEC EDGAR
Kristian ReichChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jul 20, 2026Period of report Jul 15, 20260001213900-26-079376
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 15, 2026
Class A ordinary shares, par value $0.0001 per shareF1F2F316,105$20.01$322.26K2,808,446IndirectSee footnote.
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.04. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
Open on SEC EDGAR
da Silva Jorge SantosDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Jul 13, 2026Period of report Jul 9, 20260001213900-26-077564
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 10, 2026
Class A ordinary shares, par value $0.0001 per shareF1F368,289$20.02$1.37M2,774,893Direct
SaleJul 9, 2026
Class A ordinary shares, par value $0.0001 per shareF1F233,936$20.01$679.06K2,843,182Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.03. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.10. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
da Silva Jorge SantosDirector · Chief Executive Officer
4Rule 10b5-1 plan disclosed
Filed Jul 2, 2026Period of report Jul 1, 20260001213900-26-074964
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 1, 2026
Class A ordinary shares, par value $0.0001 per shareF1F247,775$20.03$956.93K2,877,118Direct
Filing footnotes · 2
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.09. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Matthias BodenstedtChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jun 23, 2026Period of report Jun 22, 20260001213900-26-071075
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 22, 2026
Class A ordinary shares, par value $0.0001 per shareF1F239,120$22.04$862.20K1,115,435Direct
Filing footnotes · 2
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.87 to $23.2049. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Matthias BodenstedtChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Jun 18, 2026Period of report Jun 17, 20260001213900-26-070259
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 18, 2026
Class A ordinary shares, par value $0.0001 per shareF1F32,794$19.60$54.76K1,154,555Direct
SaleJun 17, 2026
Class A ordinary shares, par value $0.0001 per shareF1F215,082$19.68$296.81K1,157,349Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.505 to $19.70. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Kristian ReichChief Scientific Officer
4Rule 10b5-1 plan disclosed
Filed Jun 17, 2026Period of report Jun 15, 20260001213900-26-069753
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 17, 2026
Class A ordinary shares, par value $0.0001 per shareF1F5F350,000$19.43$971.50K2,824,551IndirectSee footnote.
SaleJun 16, 2026
Class A ordinary shares, par value $0.0001 per shareF1F4F350,000$18.70$935.00K2,874,551IndirectSee footnote.
SaleJun 15, 2026
Class A ordinary shares, par value $0.0001 per shareF1F2F350,000$18.89$944.50K2,924,551IndirectSee footnote.
Filing footnotes · 5
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.66 to $19.12. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
  4. F4The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.235 to $19.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  5. F5The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.915 to $19.97. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Matthias BodenstedtChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed May 13, 2026Period of report May 11, 20260001213900-26-055799
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMay 11, 2026
Class A ordinary shares, par value $0.0001 per shareF1F213,653$20.02$273.33K1,172,431Direct
Filing footnotes · 2
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.50 to $20.83. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Matthias BodenstedtChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Apr 16, 2026Period of report Apr 14, 20260001213900-26-044642
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 14, 2026
Class A ordinary shares, par value $0.0001 per shareF1F22,426$19.56$47.45K1,186,084Direct
Filing footnotes · 2
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.625. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
da Silva Jorge SantosDirector · Chief Executive Officer
4
Filed Apr 14, 2026Period of report Apr 10, 20260001213900-26-043647
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 13, 2026
Class A ordinary shares, par value $0.0001 per shareF3F151,873$18.23$945.64K2,924,893Direct
SaleApr 10, 2026
Class A ordinary shares, par value $0.0001 per shareF2F198,127$18.41$1.81M2,976,766Direct
Filing footnotes · 3
  1. F1Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $19.55. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Matthias BodenstedtChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Apr 10, 2026Period of report Apr 9, 20260001213900-26-042629
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleApr 10, 2026
Class A ordinary shares, par value $0.0001 per shareF1F31,925$19.51$37.56K1,188,510Direct
SaleApr 9, 2026
Class A ordinary shares, par value $0.0001 per shareF1F285,870$18.94$1.63M1,190,435Direct
Filing footnotes · 3
  1. F1This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025 to cover tax liabilities of the Reporting Person.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.340 to $19.455. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.560. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Value Fund II LP BiotechnologyDirector · 10% owner
Value Fund L P BiotechnologyDirector · 10% owner
Value Trading Fund OS LP BiotechnologyDirector · See Explanation of Responses
GP Holdings LLC BVFDirector · 10% owner
I GP LLC BVFDirector · 10% owner
II GP LLC BVFDirector · 10% owner
Inc BVFDirector · 10% owner
Partners L P BVFDirector · 10% owner
Partners OS Ltd. BVFDirector · See Explanation of Responses
Mark N LampertDirector · 10% owner
4
Filed Apr 2, 2026Period of report Mar 31, 20260000921895-26-000895
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 31, 2026
Class A Ordinary Shares, $0.0001 par valueF1F21,932,354$16.79$32.44M8,302,735Direct
SaleMar 31, 2026
Class A Ordinary Shares, $0.0001 par valueF1F31,569,116$16.79$26.35M6,599,722Direct
SaleMar 31, 2026
Class A Ordinary Shares, $0.0001 par valueF1F4248,530$16.79$4.17M1,039,238Direct
Filing footnotes · 8
  1. F1This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  2. F2Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the general parter of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
  3. F3Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
  4. F4Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
  5. F5This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to Spike Loy's continued service to the Issuer.
  6. F6This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer. This option has fully vested as of the date hereof.
  7. F7This option represents a right to purchase a total of 11,297 Class A Ordinary Shares of the Issuer. This option has fully vested as of the date hereof.
  8. F8Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Spike Loy, who serves on the Issuer's board of directors and as a Managing Director of Partners, pursuant to which Mr. Loy is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Loy disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
Open on SEC EDGAR
da Silva Jorge SantosDirector · Chief Executive Officer
4
Filed Dec 10, 2025Period of report Dec 8, 20250001213900-25-120106
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 9, 2025
Class A ordinary shares, par value $0.0001 per shareF170,000$14.49$1.01M2,878,577Direct
SaleDec 8, 2025
Class A ordinary shares, par value $0.0001 per shareF2F1130,000$15.08$1.96M2,948,577Direct
Filing footnotes · 2
  1. F1Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.045789 to $15.098641. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Kristian ReichChief Scientific Officer
4
Filed Dec 10, 2025Period of report Dec 8, 20250001213900-25-120105
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 9, 2025
Class A ordinary shares, par value $0.0001 per shareF172,908$14.43$1.05M0Direct
SaleDec 8, 2025
Class A ordinary shares, par value $0.0001 per shareF2F1130,000$15.08$1.96M72,908Direct
Filing footnotes · 3
  1. F1Sales made pursuant to Rule 144 under the Securities Act of 1933, as amended, to cover tax liabilities of the Reporting Person and other expenses incurred related to the sales.
  2. F2The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $15.036949 to $15.101507. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. F3Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.